Friday, December 28, 2012 Thursday, December 27, 2012- This Biotech Is Opportunistic With Recent CEO Buysat Motley Fool (Thu, Dec 27)
- Pfizer’s Backing Spurs Halozyme's Growthat Motley Fool (Thu, Dec 27)
- InterMune Insider Trading, Depomed Drops Lawsuits: Healthcare Business Updateat Wall St. Cheat Sheet (Thu, Dec 27)
- What a Weak Yen Does to Corporate Earningsat CNBC (Thu, Dec 27)
- A Must Buy Dog of the Dowat Motley Fool (Thu, Dec 27)
- How Abbott Labs Succeeded in 2012at Motley Fool (Thu, Dec 27)
- Wall Street Transcript Interview with Manuel A. Henriquez, Co-Founder, Chairman and CEO of Hercules Technology Growth Capital (HTGC)Wall Street Transcript (Thu, Dec 27)
- Auxilium files for approval of Xiaflex as Peyronie’s disease treatmentat bizjournals.com (Thu, Dec 27)
- 2 Future Dow Leaders Rise and a Former Kingpin Fallsat Motley Fool (Thu, Dec 27)
- Despite Political Obstacles, Healthcare Multinationals Flock To Chinaat Seeking Alpha (Thu, Dec 27)
- Does Lilly's Lineup Make the Grade?at Motley Fool (Thu, Dec 27)
- [video] Corporate America's Yen Challengeat CNBC (Thu, Dec 27)
- Rheumatoid Arthritis Review – Focus Eli Lilyat Motley Fool (Thu, Dec 27)
- Keep an Eye on These Five New Drugs in the First Quarter of 2013at Minyanville (Thu, Dec 27)
- Japanese Approval for EliquisZacks (Thu, Dec 27)
- Toyota Accord Lawyers Seek $200 Million Feeat Bloomberg (Thu, Dec 27)
- Verizon Settles With YMax and 3 Dow Movers to Followat Wall St. Cheat Sheet (Thu, Dec 27)
Wednesday, December 26, 2012Add PFE News to My Yahoo!   | |
|
0.08(0.28%) 9:50AM EDT - Nasdaq Real Time Price